Rachel Vatnsdal
Stock Analyst at JP Morgan
(3.22)
# 736
Out of 4,583 analysts
49
Total ratings
48.28%
Success rate
3.36%
Average return
Main Sectors:
Stocks Rated by Rachel Vatnsdal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HSIC Henry Schein | Maintains: Overweight | $88 → $80 | $71.41 | +12.03% | 3 | Aug 12, 2024 | |
| NVST Envista Holdings | Downgrades: Neutral | $23 → $16 | $18.88 | -15.25% | 3 | Aug 8, 2024 | |
| TEM Tempus AI | Maintains: Overweight | $42 → $47 | $51.98 | -9.58% | 2 | Aug 7, 2024 | |
| MYGN Myriad Genetics | Maintains: Underweight | $17 → $20 | $27.19 | -26.43% | 3 | Aug 7, 2024 | |
| AKYA Akoya Biosciences | Downgrades: Neutral | n/a | $2.92 | - | 2 | Aug 6, 2024 | |
| MTD Mettler-Toledo International | Maintains: Neutral | $1,300 → $1,400 | $1,389.19 | +0.78% | 2 | Aug 5, 2024 | |
| ADPT Adaptive Biotechnologies | Maintains: Overweight | $5 → $6 | $4.58 | +31.00% | 4 | Aug 2, 2024 | |
| RGEN Repligen | Maintains: Overweight | $190 → $200 | $142.34 | +40.51% | 4 | Jul 31, 2024 | |
| RVTY Revvity | Maintains: Neutral | $105 → $120 | $122.74 | -2.23% | 3 | Jul 30, 2024 | |
| TXG 10x Genomics | Downgrades: Neutral | $40 → $20 | $22.17 | -9.77% | 1 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $165 → $155 | $138.45 | +11.95% | 5 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $600 → $650 | $610.39 | +6.49% | 7 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.91 | - | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $60 → $90 | $66.75 | +34.83% | 2 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $270 | $271.91 | -0.70% | 4 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $260 → $250 | $331.29 | -24.54% | 2 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $45 | $59.95 | -24.94% | 1 | May 22, 2023 |
Henry Schein
Aug 12, 2024
Maintains: Overweight
Price Target: $88 → $80
Current: $71.41
Upside: +12.03%
Envista Holdings
Aug 8, 2024
Downgrades: Neutral
Price Target: $23 → $16
Current: $18.88
Upside: -15.25%
Tempus AI
Aug 7, 2024
Maintains: Overweight
Price Target: $42 → $47
Current: $51.98
Upside: -9.58%
Myriad Genetics
Aug 7, 2024
Maintains: Underweight
Price Target: $17 → $20
Current: $27.19
Upside: -26.43%
Akoya Biosciences
Aug 6, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.92
Upside: -
Mettler-Toledo International
Aug 5, 2024
Maintains: Neutral
Price Target: $1,300 → $1,400
Current: $1,389.19
Upside: +0.78%
Adaptive Biotechnologies
Aug 2, 2024
Maintains: Overweight
Price Target: $5 → $6
Current: $4.58
Upside: +31.00%
Repligen
Jul 31, 2024
Maintains: Overweight
Price Target: $190 → $200
Current: $142.34
Upside: +40.51%
Revvity
Jul 30, 2024
Maintains: Neutral
Price Target: $105 → $120
Current: $122.74
Upside: -2.23%
10x Genomics
Jul 18, 2024
Downgrades: Neutral
Price Target: $40 → $20
Current: $22.17
Upside: -9.77%
May 30, 2024
Maintains: Overweight
Price Target: $165 → $155
Current: $138.45
Upside: +11.95%
Apr 25, 2024
Maintains: Overweight
Price Target: $600 → $650
Current: $610.39
Upside: +6.49%
Apr 22, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.91
Upside: -
Feb 14, 2024
Upgrades: Overweight
Price Target: $60 → $90
Current: $66.75
Upside: +34.83%
Dec 20, 2023
Maintains: Overweight
Price Target: $250 → $270
Current: $271.91
Upside: -0.70%
Nov 8, 2023
Maintains: Neutral
Price Target: $260 → $250
Current: $331.29
Upside: -24.54%
May 22, 2023
Downgrades: Neutral
Price Target: $90 → $45
Current: $59.95
Upside: -24.94%